Print

pSivida Corp (PSDV) Reports Fourth Quarter and Fiscal Year 2013 Results  
9/26/2013 6:44:48 AM

biotech jobs post your resume Help employers find you! Check out all the jobs and post your resume.

pSivida Corp. (NASDAQ: PSDV)(ASX: PVA), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, today announced financial results for its fourth quarter and fiscal year ended June 30, 2013.

“In fiscal 2013, we made a major step forward in our transition to a Specialty Pharma company with the start of the first of two planned pivotal Phase III clinical trials for our own lead development product, the micro-insert Medidur™ for posterior uveitis,” said Dr. Paul Ashton, President and CEO of pSivida.

Help employers find you! Check out all the jobs and post your resume.

//-->